Literature DB >> 15009382

Immunoglobulin therapy: history, indications, and routes of administration.

Catherine R Weiler1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15009382     DOI： 10.1111/j.1365-4632.2004.02236.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  4 in total

Review 1.  Subcutaneous immunoglobulin: opportunities and outlook.

Authors:  S Misbah; M H Sturzenegger; M Borte; R S Shapiro; R L Wasserman; M Berger; H D Ochs
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

2.  Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency.

Authors:  F Hoffmann; B Grimbacher; J Thiel; H-H Peter; B H Belohradsky
Journal:  Eur J Med Res       Date:  2010-06-28       Impact factor: 2.175

3.  Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

Authors:  Clementina Canessa; Jessica Iacopelli; Antonio Pecoraro; Giuseppe Spadaro; Andrea Matucci; Cinzia Milito; Alessandra Vultaggio; Carlo Agostini; Francesco Cinetto; Maria Giovanna Danieli; Simona Gambini; Carolina Marasco; Antonino Trizzino; Angelo Vacca; Domenico De Mattia; Baldassarre Martire; Alessandro Plebani; Mario Di Gioacchino; Alessia Gatta; Andrea Finocchi; Francesco Licciardi; Silvana Martino; Marco De Carli; Viviana Moschese; Chiara Azzari
Journal:  Int J Immunopathol Pharmacol       Date:  2016-12-07       Impact factor: 3.219

4.  Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.

Authors:  Christine Anterasian; Richard Duong; Peg Gruenemeier; Carol Ernst; Jessica Kitsen; Bob Geng
Journal:  J Clin Immunol       Date:  2019-11-01       Impact factor: 8.542
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.